Skip to main content
. 2020 Jun 19;40(6):BSR20201199. doi: 10.1042/BSR20201199

Figure 2. The growth inhibition rate of compounds against human gastric cancer cells and human gastric mucosal cells.

Figure 2

(A–C) BGC-823, SGC-7901 and GES-1 cells were treated with ISL analogues (ISL-1 to ISL-18) or ISL at 20 μM for 48 h and then cell viability was determined by MTS assay. (D,E) BGC-823 and SGC-7901 cells were treated with ISL-17 or ISL by concentration gradient (2.5, 5, 10, 20 and 40 μM) for 48 h, and then cell viability was determined by MTS assay.